Patents by Inventor Wassim Hodroj

Wassim Hodroj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith
    Patent number: 8632979
    Abstract: The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: January 21, 2014
    Assignees: Albert Einstein College of Medicine of Yeshiva University, University of Lausanne
    Inventors: Ian M. Willis, Nouria Hernandez, Wassim Hodroj
  • METHODS FOR DETERMINING AGENTS THAT TREAT OR PREVENT OBESITY AND/OR OBESITY RELATED DISEASES AND METHODS FOR TREATMENT THEREWITH
    Publication number: 20120128690
    Abstract: The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875.
    Type: Application
    Filed: November 17, 2011
    Publication date: May 24, 2012
    Applicants: University of Lausanne, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Ian M. Willis, Nouria Hernandez, Wassim Hodroj
  • Use of an angiotensin IV antagonist to treat insulin resistance or cardiovascular risk related to metabolic syndrome
    Publication number: 20090012005
    Abstract: The present invention relates to the use of an angiotensin IV antagonist that decreases the effects on angiotensinogen expression of angiotensin IV in vascular smooth muscle cells for preparing a drug to treat or prevent type II diabetes, insulin resistance or cardiovascular risk related to metabolic syndrome, as well as to pharmaceutical compositions comprising one such antagonist.
    Type: Application
    Filed: April 28, 2008
    Publication date: January 8, 2009
    Inventors: Giampiero Bricca, Jacques Randon, Wassim Hodroj, Georges P. Vauquelin, Dirk Tourwe